A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5518-5518 ◽  
Author(s):  
H. Mackay ◽  
H. W. Hirte ◽  
A. Covens ◽  
K. MacAlpine ◽  
L. Wang ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Phase Ii ◽  
Histone Deacetylase Inhibitor ◽  
Phase Ii Trial ◽  
Ovarian Tumors ◽  
Platinum Resistant ◽  
Deacetylase Inhibitor

scholarly journals Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

Oral Oncology ◽  
2012 ◽  
Vol 48 (12) ◽  
pp. 1281-1288 ◽  
Author(s):  
Missak Haigentz ◽  
Mimi Kim ◽  
Catherine Sarta ◽  
Juan Lin ◽  
Roger S. Keresztes ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Histone Deacetylase ◽  
Phase Ii ◽  
Neck Cancer ◽  
Histone Deacetylase Inhibitor ◽  
Phase Ii Trial ◽  
Deacetylase Inhibitor

scholarly journals A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low‐Grade Neuroendocrine Tumors

2016 ◽  
Vol 21 (7) ◽  
pp. 785 ◽  
Author(s):  
Ning Jin ◽  
Sam J. Lubner ◽  
Daniel L. Mulkerin ◽  
Saurabh Rajguru ◽  
Lakeesha Carmichael ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Neuroendocrine Tumors ◽  
Phase Ii ◽  
Histone Deacetylase Inhibitor ◽  
Phase Ii Trial ◽  
Low Grade ◽  
Deacetylase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document